Skip to main content
TECON BIOLOGY Co.LTD logo

TECON BIOLOGY Co.LTD — Investor Relations & Filings

Ticker · 002100 ISIN · CNE000001PZ9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,493 across all filing types
Latest filing 2024-08-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002100

About TECON BIOLOGY Co.LTD

https://www.tcsw.com.cn

TECON BIOLOGY Co.LTD operates an integrated industrial chain focused on animal health and nutrition. The company specializes in the research, development, and manufacturing of veterinary biological products, including a comprehensive range of vaccines and diagnostic reagents for livestock. Its operations encompass the production of high-quality animal feed and the management of large-scale breeding programs, with a primary focus on pig farming and meat processing. By leveraging advanced biotechnology and standardized production systems, the company provides comprehensive solutions for livestock management and food safety. Key activities include the formulation of specialized animal nutrition products and the implementation of rigorous biosecurity protocols across its facilities to ensure the quality and reliability of its agricultural outputs.

Recent filings

Filing Released Lang Actions
半年报监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board (监事会) of Tian Kang Bio (天康生物股份有限公司) regarding the approval of the company's 2024 semi-annual report and a special report on the use of raised funds. It references the full semi-annual report and the special report being published elsewhere (in newspapers and on the cninfo website), indicating this document itself is not the report but an announcement of the supervisory board's meeting resolutions. The document length is short (1069 characters), and it mainly serves to announce the meeting decisions and approvals, not to present the financial data or detailed report content. Therefore, it fits best as a Regulatory Filing (RNS) because it is a formal announcement related to regulatory compliance and meeting resolutions, not the actual semi-annual report (IR) or a report publication announcement (RPA) since it contains substantive meeting resolution content rather than just a notice of report publication.
2024-08-28 Chinese
半年报董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from Tian Kang Biological Co., Ltd. regarding the resolutions passed at the 19th meeting of the 8th Board of Directors. It includes the appointment of senior management personnel and approval of the 2024 semi-annual report and related fundraising usage report. The document primarily focuses on board decisions and management appointments, with detailed biographies of the newly appointed vice general managers. It does not contain the full semi-annual report itself but references where it can be found. The key content is about changes in senior management and board resolutions, which fits the category of Board/Management Information (MANG). The document length is 2294 characters, relatively short and more of an announcement of decisions rather than a full financial report or detailed management discussion. Therefore, the best classification is MANG with high confidence.
2024-08-28 Chinese
半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 95% confidence The document is a summary table detailing the non-operating fund occupation and other related party fund transactions for the first half of 2024. It includes specific financial figures related to intercompany loans and balances, with a focus on related party transactions. The document is relatively short (1350 characters) and contains detailed financial data for a half-year period. This matches the characteristics of an Interim / Quarterly Report (IR), which provides substantive financial data and analysis for a period shorter than a full fiscal year. It is not an announcement or a certification, but actual financial data. Therefore, the appropriate classification is IR. H1 2024
2024-08-28 Chinese
2024年第四次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the resolutions passed at the 2024 fourth extraordinary general meeting of shareholders of Tian Kang Bio Co., Ltd. It details the meeting date, attendance, voting results, and legal opinions on the meeting's validity. It does not contain full financial statements or detailed financial performance data. The document is a formal announcement of voting results from a shareholder meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1761 characters), and it is not a full report but an announcement of meeting outcomes and voting results.
2024-08-12 Chinese
关于天康生物股份有限公司2024年第四次临时股东大会之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance, and voting results of the 2024 fourth extraordinary general meeting of shareholders of Tian Kang Bio. It details the legality of the meeting's call, attendance qualifications, voting procedures, and the validity of the resolutions passed. The document is not the meeting materials themselves, nor is it a voting result announcement or a proxy solicitation. It is a legal opinion related to the shareholders meeting, which is a type of Board/Management Information or related governance documentation. However, since it is a legal opinion letter specifically about the shareholders meeting procedures and legality, it does not fit into AGM Information (which is presentations/materials), nor DVA (which is voting results announcement). It is best classified under Regulatory Filings (RNS) as a legal compliance document related to corporate governance and meeting legality. The document length is under 5,000 characters and is a standalone legal opinion, not the meeting report or minutes themselves.
2024-08-12 Chinese
关于2024年7月份生猪销售简报
Regulatory Filings Classification · 95% confidence The document is a sales brief for July 2024 from Tian Kang Biological Co., Ltd., detailing monthly and cumulative sales volumes and revenues of live pigs. It includes sales data tables, risk warnings, and a disclaimer that the data is unaudited and for investor reference only. The document is short (1724 characters) and focuses on operational sales data rather than comprehensive financial statements or management analysis. It does not present a full quarterly or annual financial report, nor does it announce a report publication or voting results. It is a periodic sales update, which does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. Given the nature and length, the best fitting category is Regulatory Filings (RNS), as it is a general regulatory announcement providing operational data without full financial statements or detailed analysis.
2024-08-09 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.